Indomethacin to the rescue of TRAIL-resistant melanomas.
Patients with melanomas develop resistance to both conventional- and targeted-therapy drugs. Promising clinical responses with immune checkpoint reagents have resulted in renewed interest in the use of biological therapies, although only subsets of individuals are known to respond to these reagents. Tse et al. now report on the use of indomethacin, an anti-inflammatory drug, to sensitize therapy-resistant melanoma cells.